FDA Approved: VITRAKVI — Supplemental Application (Loxo Oncology, Inc.)

View source ↗

Summary

FDA approved a supplemental application for VITRAKVI (larotrectinib) to expand its labeling for patients with solid tumors that harbor NTRK gene fusions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ntrk Gene Fusion Solid Tumors

Drugs mentioned

• Vitrakvi (larotrectinib)

Snippet

SUPPL AP for VITRAKVI (LAROTRECTINIB)